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Abstract
Objective The aim of this prospective study was to evaluate the efficacy of sialendoscopy in the management of adult chronic 
recurrent parotitis without sialolithiasis. In addition, preliminary results of an initial randomized placebo-controlled trial of 
single-dose intraductal steroid injection given concurrently with sialendoscopy, are presented.
Methods Forty-nine adult patients with chronic recurrent parotitis without sialoliths were included in this study. They under-
went sialendoscopy and were randomized to receive either a concurrent intraductal injection of isotonic saline solution or 
125 mg of hydrocortisone. Symptom severity was evaluated with visual analogue scale (VAS) and by recording symptom 
frequency and course with a multiple-choice questionnaire completed preoperatively and at 3, 6, and 12 months after the 
procedure.
Results The mean VAS score was 5.6 preoperatively and dropped to 2.9 at 3 months, 3.0 at 6 months, and 2.7 at 12 months 
after the procedure. The VAS score and the frequency of symptoms were significantly lower at 3 (p < 0.001), 6 (p < 0.001) 
and 12 (p < 0.001) months after the procedure when compared with the preoperative scores indicating that sialendoscopy 
reduces the symptoms of recurrent parotitis. However, complete permanent resolution of symptoms was rare. Single-dose 
steroid injection concomitant to sialendoscopy provided no additional benefit, but the current study is not sufficiently powered 
to determine a clinical difference between the steroid and non-steroid groups.
Conlusion Sialendoscopy appears to reduce the symptoms of chronic recurrent parotitis. While total permanent symptom 
remission is rare, sialendoscopy can be considered a safe and relatively efficacious treatment method for this patient group.
Keywords Chronic recurrent parotitis · Sialendoscopy · Sialadenitis · Steroids
Introduction
Chronic recurrent parotitis is an inflammatory condition 
characterized by periodic or persistent unilateral or bilateral 
swelling and tenderness of the parotid gland(s). The exact 
pathogenesis is not fully understood, but the primary patho-
physiological event is believed to be due to decreased sali-
vary secretion or obstructive salivary stagnation. Insufficient 
salivary flow can lead to ascending salivary duct infection 
via the oral cavity and potentially will progress to acute 
bacterial infection or frequent opportunistic infections [1]. 
Recurrent inflammation may lead to sialectasis formation, 
acinar destruction, fibrosis, and chronic inflammatory cell 
infiltration, thus further reducing salivary flow [2, 3]. Ductal 
obstruction may be caused by many etiological factors, 
including sialoliths, strictures, stenosis, mucous plugs, pol-
yps, and foreign bodies [4]. Non-obstructive factors, such 
as radiation damage and autoimmune disease, may also 
decrease saliva secretion and flow [5]. In many cases, how-
ever, the etiology is unclear.
Primary treatment of chronic parotitis is conservative, 
i.e., NSAIDs, sialogogues, mouth rinses, gland massage, and 
in case of an acute purulent infection, antibiotics [1, 6]. Inva-
sive approaches include tympanic neurectomy and super-
ficial or total parotidectomy as a final option [1]. Salivary 
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duct ligation has also been described, but is currently rarely 
performed due to high failure rate [7, 8].
The development of modern sialendoscopy has allowed 
improved visual access into the salivary duct system to 
diagnose and treat obstructive causes. Sialendoscopy can 
be performed under local anesthesia with minimal morbid-
ity [9, 10]. Good results have been achieved in the treatment 
of sialolithiasis and ductal stenosis or strictures [11]. There 
is some preliminary evidence that sialendoscopy can also 
relieve symptoms of autoimmune-mediated salivary gland 
diseases [12]. Despite these advances, patients with chronic 
recurrent sialadenitis without sialolithiasis often have persis-
tent or recurrent symptoms [13]. Intraductal steroid irriga-
tions are frequently used concurrently with sialendoscopy to 
manage these patients.
The aim of this study was to prospectively evaluate the 
efficacy of sialendoscopy in the treatment of chronic recur-
rent parotitis without sialolithiasis and try to provide pre-
liminary results from the benefits of single-dose intraductal 
hydrocortisone given concurrently with sialendoscopy.
Materials and methods
The institutional Research Ethics Committee approved the 
study design and research permission was granted. The Dec-
laration of Helsinki 2013 guidelines and protocols were fol-
lowed. Informed consent was obtained from all individual 
participants included in the study.
This prospective study was conducted at the Department 
of Otorhinolaryngology-Head and Neck Surgery, Helsinki 
University Hospital, Helsinki, Finland, between March 2012 
and December 2015. In total, 54 patients gave their consent 
to participate in this study. However, five recruited patients 
were subsequently excluded due to spontaneous symptom 
improvement; by the time of the endoscopy these patients 
no longer fulfilled the inclusion criteria. Overall, 49 patients 
were included in the study. All patients had a history of 
recurrent or persistent swelling of the parotid gland(s) with 
or without pain, which significantly reduced their quality 
of life. The inclusion criteria were at least three prolonged 
(over 24 h) or ten shorter episodes of parotid swelling dur-
ing the last 6 months prior to sialendoscopy. Ultrasound 
examination or, in some cases, MRI was performed before 
sialendoscopy and patients with sialoliths were excluded 
from the study.
The sialendoscopies were performed under local anesthe-
sia as day surgery procedures using all-in-one and interven-
tional 1.1 or 1.3 mm sialendoscopes (Karl Storz: 11573 A 
and 11575 A). The ductal system was explored under con-
tinuous lavage with isotonic saline solution to enhance the 
visualization and to remove debris and mucus plaques. 
If strictures were encountered, an attempt was made to 
gently dilate them with the endoscope itself, a salivary duct 
probe, or a micro drill. During the endoscopic procedure, 
the patients were randomized in a double-blind fashion at 
a 1:1 ratio to receive either 1 mL of isotonic saline solu-
tion (group A, n = 24) or 1 mL of hydrocortisone 125 mg/
mL (group B, n = 25) intraductally. The 1 mL of isotonic 
saline or hydrocortisone was given after the sialendoscopic 
procedure under visual control, and the gland was emptied 
from rinsing solution by milking it beforehand. If a patient 
had bilateral symptoms, sialendoscopy was performed for 
the gland with more symptoms, and in some cases, for both 
glands with identical technique. Gland massage was recom-
mended from the following day on. Pre- or postoperative 
antibiotics were not used.
We designed a questionnaire to assess the severity and 
frequency of parotid symptoms. The severity of symptoms 
was evaluated by means of a visual analogue scale (VAS, 
horizontal line of 10 cm) from 0 (no symptoms) to 10 (the 
worst possible symptoms). Patients were asked to esti-
mate the intensity of symptoms during the last 3 months 
and mark the average score on the VAS line. The symp-
tom frequency and course were evaluated with categorical 
questions. Patients were requested to estimate the frequency 
of symptoms during the last 3 months and mark the most 
suitable option. These categories appear in Fig. 1. In addi-
tion, patients were asked to estimate if their symptoms had 
resolved completely, decreased significantly, decreased a lit-
tle, remained unchanged, increased a little or increased sig-
nificantly during the last 3 months. The patients completed 
questionnaires and VAS before sialendoscopy and 3, 6, and 
12 months after the procedure. An outpatient control visit 
was conducted on average 3 months after the sialendoscopy.
We gathered data on patient demographics, medical 
history, dental status (prostheses, implants, bridges etc.,) 
tobacco smoking, imaging findings, sialendoscopy findings, 
interventions, complications, and possible further treatments 
from the medical records and prequestionnaire forms. Stric-
ture was defined as a local narrowing or obstruction of the 
duct, and duct stenosis as a longer or generalized narrowing 
of the duct. If the patient had disruptive persistent parotid 
symptoms at a follow-up visit 3 months after the procedure 
or later, ductal saline lavage followed by an intraductal cor-
tisone injection could be administered at an outpatient clinic. 
These patients were excluded from later analyses. Patients 
with incomplete follow-up information at some time point 
were excluded from analyzes at that point. Eventually, 49 
patients were included for the analyses at 3 months post-
operatively, 38 patients at 6 months postoperatively and 42 
patients at 12 months postoperatively.
Descriptive statistics were used to analyze the demo-
graphic and clinical characteristics of the study population. 
The answers are given as absolute numbers and percentages 
or mean values.
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Comparison of symptom frequency and VAS scores 
before and after sialendoscopy were performed using the 
Wilcoxon non-parametric signed-rank test by analyzing the 
within-subject change. The comparability of subgroups A 
and B were assessed using Chi-square test and Fisher’s exact 
tests. The frequency of symptoms and VAS scores were 
compared between groups A and B using equal-variance t 
test and analysis of covariance report.
Relationships between demographic, clinical and endo-
scopic variables, and VAS scores were assessed by means of 
the t test, the analysis of covariance report and the Spearman 
rank-correlation test.
A p value less than 0.05 was considered to indicate statis-
tical significance. The analyses were performed using NCSS 
8 statistical software.
Results
A total of 49 patients participated in this study. Demo-
graphic and clinical characteristics of the whole series are 
presented in Table 1. The mean patient age was 53 years 
(range 21–75). Thirty-three (67%) patients were women, 6 
(12%) had been diagnosed with an autoimmune disease and 
31 (63%) were smokers or had stopped smoking recently. 
All patients had recurrent swelling of the parotid gland with 
tenderness of the gland, 19 (39%) had also significant pain, 
and 8 (16%) had suffered from recurrent bacterial infec-
tions. The average symptom duration was 7.2 years (median 
4.5 years; range 0.5–41). Twelve (24%) patients had had 
their first symptoms decades ago, after which they had been 
symptom-free until the symptoms recurred a few years prior 
to the sialendoscopy.
Ultrasound was performed for 47 (96%) patients preop-
eratively and MRI for 3 (6%). Ductal dilation (n = 11, 22%) 
and heterogeneity of the parenchyma with small hypoechoic 
or anechoic areas (n = 10, 20%) were the most common 
imaging findings. Small cysts were found in two MRIs.
The most frequent finding in sialendoscopy were mucous 
plugs (n = 28, 57%), followed by stricture of the duct 
(n = 21, 43%), dilation of the duct (n = 10, 20%), stenosis 
of the duct (n = 8, 16%), and sialodochitis (n = 5, 10%). In 
12 (24%) patients only a small amount of mucous exudate 
was found in an otherwise normal ductal system. A stricture 
was opened and dilated in 17 (35%) patients. Eight patients 
(16%) had bilateral sialendoscopy.
Forty-seven (96%) patients had a follow-up visit approx-
imately 3 months after the operation. Further visits were 
Fig. 1  Frequency of symptoms at 3 months preoperatively and at 3, 6, and 12 months postoperatively
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arranged as needed. Six (12%) patients received intraductal 
cortisone injection(s) 3–8 months after the sialendoscopy 
at an outpatient clinic. One of these patients also received 
botulinum toxin A injections, and another patient underwent 
tympanic neurectomy. These patients were excluded from 
future analyses.
The mean VAS score was 5.6 preoperatively and 
2.9 at 3 months, 3.0 at 6 months, and 2.7 at 12 months 
postoperatively in the whole study group. The average 
VAS score change was − 2.7, − 2.6 and − 2.9 at 3, 6 and 
12 months postoperatively, respectively. The VAS score was 
significantly lower at 3 (p < 0.001), 6 (p < 0.001), and 12 
(p < 0.001) months after the operation compared to the pre-
operative VAS score when the change was measured individ-
ually. The symptom frequency was also significantly lower 
when comparing the symptoms at 3 months preoperatively 
to the symptoms at 3 months postoperatively (p < 0.001), 
at 6 months postoperatively (p < 0.001), and at 12 months 
postoperatively (p < 0.001). Patients with higher VAS scores 
preoperatively had a smaller VAS change postoperatively 
(p = 0.024).
Gender, age, clinical characteristics (autoimmune disease, 
tobacco smoking, teeth status), duration of symptoms before 
sialendoscopy, endoscopic findings (mucous plugs, stricture, 
stenosis, dilation of the duct, sialodochitis), or dilation of a 
stricture did not correlate with a better or worse postopera-
tive result when measured by means of VAS score change.
The symptom frequency at 3 months preoperatively and 
at 3, 6, and 12 months postoperatively is shown in Fig. 1. 
At 3 months after the operation, 27% of the patients were 
symptom-free, symptoms decreased significantly in 31%, 
decreased slightly in 20%, remained unchanged in 18%, 
and increased slightly in 4% based on the patients’ self-
assessment. However, at 12 months postoperatively only one 
patient (2%) had been symptom-free for the whole follow-up 
time.
In subgroup analyses, no significant difference was 
observed between the saline group (group A) and the hydro-
cortisone group (group B) in VAS scores or in symptom 
frequency at 3 or 12 months postoperatively. The mean and 
median VAS scores of groups A and B at each time point are 
presented in Fig. 2. Groups A and B were comparable in the 
terms of demographic characteristics (gender, age), clinical 
characteristics (autoimmune disease, tobacco smoking, teeth 
status), endoscopic findings, and preoperative VAS scores, 
as well as the duration and frequency of symptoms before 
sialendoscopy.
Discussion
The management of chronic parotitis remains challenging 
and primary treatment consists of conservative approaches. 
The aim of treatment is to stimulate saliva secretion and to 
maintain good oral hygiene to reduce the risk of ascend-
ing infections. These methods have the potential to control 
the symptoms in mild cases [8]. However, there are only 
few studies published on conservative treatment, [1] and 
the number of studies on the treatment of chronic recur-
rent parotitis with sialendoscopy is also limited [11, 14, 15]. 
Therefore, we performed a prospective study on 49 adult 
Table 1  Demographic, clinical, and endoscopic characteristics
Characteristics Total (49 patients)
Demographic and preoperative characteristics
Women (%) 33 (67)
Mean age (years) 53
Tobacco smoking (%) 31 (63)
Autoimmune disease (%) 6 (12)
































  Steroid irrigation 6 (12)
  Botox injection 1 (2)
  Tympanic neurectomy 1 (2)
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patients with chronic recurrent parotitis to evaluate the effi-
cacy of sialendoscopy with or wihtout a concurrent single-
dose intraductal corticosteroid.
A retrospective study by Watkin et al. concluded that out 
of 30 adults with chronic parotitis with punctuate sialectasis 
but with no sialoliths on sialography, 56% showed spontane-
ous improvement with symptomatic treatment alone [16]. 
In our study, symptoms were substantially reduced in five 
patients while waiting for endoscopy and their procedure 
was accordingly cancelled. It is clear, that a wait-and-see 
approach may be considered for patients with mild symp-
toms, since it seems that the disease has a fluctuating natural 
course and some symptoms tend to resolve spontaneously.
It has been proposed that serum proteins accumulate in 
the salivary ducts and further coagulate as a consequence 
of gland inflammation, thus causing obstruction, further 
inflammation, and damage. Hence, Baurmash suggests that 
treatment should be directed against both gland inflamma-
tion with steroids as well as precipitated serum proteins with 
rapid and complete removal via dilation, saline irrigation, 
and milking of the gland [7]. Intraductal instillation of dif-
ferent agents, such as tetracycline or methyl violet (which 
theoretically induce acinar atrophy), has also been proposed 
for treatment of chronic parotitis [8, 17]. Surgical manage-
ment approaches include salivary duct ligation, tympanic 
neurectomy, and parotidectomy. Ductoplasty outcomes have 
been disappointing with a high failure rate [1]. In a series 
of 49 patients, favorable results were achieved by tympanic 
neurectomy, with resolution or reduction of symptoms in 
82% of cases [18]. Success rates of 90 to 100% have been 
reported after superficial or total parotidectomy [1, 19, 20]. 
In the present study, tympanic neurectomy was performed 
on one patient with subsequent symptom relief. One patient 
received botulinum toxin A, which temporarily alleviated 
her symptoms. During the last decade in our department, 
we have not included parotidectomy in the management 
of patients with chronic recurrent parotitis due to its inva-
sive nature, risk of complications, and due to the success 
achieved with more conservative approaches.
The development of sialendoscopy has improved both 
the diagnosis and treatment of obstructive sialadenitis [4, 
9]. It seems that also patients with inflammatory conditions 
and autoimmune disease may benefit from sialendoscopy 
[12, 21, 22]. Based on our results, sialendoscopy reduces 
the symptoms of chronic recurrent parotitis. Sialendoscopic 
findings, demographic or clinical characteristics had no 
Fig. 2  The VAS scores of groups A and B at 3 months preoperatively and at 3, 6, and 12 months postoperatively. The whiskers represent the 
highest and the lowest VAS scores, the horizontal line represents the median VAS score and the cross represents the mean VAS score
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correlation with clinical outcome, but it seems that patients 
with higher VAS scores preoperatively had smaller reduction 
of symptoms. Over three quarters of the patients experienced 
subjective symptom improvement 3 months postoperatively. 
Still, over 20% of patients did not benefit from sialendoscopy 
and during a 12-month follow up, only one patient remained 
completely asymptomatic. This might be due to irrevers-
ible changes in the gland caused by chronic sialadenitis and 
decreased salivary flow, which predispose to new obstructive 
changes and inflammation. The role of repeated procedures 
in this patient group should be further studied.
Simple lavage of the ductal system can also help remove 
debris and dilate the duct with hydrostatic pressure and, 
therefore, the benefit of the endoscopy itself remains some-
what unclear. The advantage of sialendoscopy is the pos-
sibility to simultaneously treat obstructive pathology, such 
as occult sialoliths or strictures. Sialendoscopy also enables 
more effective irrigation under visual control.
Intraductal steroid concurrently with sialendoscopy is 
widely used especially in cases of chronic inflammation, 
stricture dilation, and stenosis [11, 23]. However, there are 
only a limited number of studies investigating the role of 
intraductal steroids in treatment of chronic sialadenitis. In a 
randomized cross-sectional study on 54 patients, Capaccio 
et al. concluded that a combination of interventional sialen-
doscopy followed by repeated ductal steroid irrigations at the 
outpatient clinic produced a better outcome than sialendos-
copy alone in the treatment of recurrent sine causa sialad-
enitis [24]. Same kind of preliminary results were found in 
a study of 22 patients with Sjögren syndrome and major 
salivary gland swelling [25]. Intraductal steroids were also 
evaluated and found efficacious in pediatric patients with 
juvenile recurrent parotitis treated with ductal hydrocor-
tisone infusion through a catheter inserted in the parotid 
duct, [26] and in a study on salivary glands affected by auto-
immune disease treated with sialendoscopy and an intra-
ductal hydrocortisone injection [12]. However, there were 
no control groups in these studies. Delagnes et al. observed 
that the use of triamcinolone irrigation concurrently with 
sialendoscopy was associated with better symptom resolu-
tion in patients with sialadenitis without sialoliths. However, 
in multivariate analysis, this finding was not statistically sig-
nificant [22]. We found no additional benefit in symptom 
relief from a single-dose intraductal steroid.
There is some heterogeneity in our study population. 
We had a female predominance, which has also been 
detected in other studies of chronic parotitis [5]. Six 
patients had been diagnosed with autoimmune disease 
and the duration of symptoms varied from 6 months to 
decades. Patients with longer symptom duration (p = 0.04) 
and female patients (p = 0.045) had higher VAS scores pre-
operatively, but no correlation with postoperative results 
was found. Interestingly, 63% of patients were smokers 
or had stopped smoking recently. According to the Finn-
ish National Institute for Health and Welfare, less than 
20% of Finnish adults currently smoke. The etiological 
role of smoking in chronic parotitis remains unclear, 
but this poses the question if tobacco can predispose to 
chronic sialadenitis. In our series, the follow-up period of 
12 months was longer than that presented in many previ-
ous studies, but still relatively short for the observation of 
this patient group with chronic recurrent symptoms.
Our study has some limitations. The lack of a validated 
symptom outcome questionnaire may be considered a 
substantial weakness. In our study setting, the patients 
had to assess the average frequency and intensity of their 
symptoms during last 3 months and this may have led 
to some memory bias. In addition, our study cohort was 
relatively small particularly for subgroup analysis. Post-
operative VAS scores were highly variable and with this 
group size only a substantial effect of steroids would have 
been detectable. It is possible that intraductal steroids 
have some benefits, but we were not able to demonstrate 
them. Hence, further studies with larger patient series are 
needed to clarify the role of intraductal steroid therapy in 
the treatment of chronic recurrent parotitis.
Conclusion
Sialendoscopy appears to reduce the symptoms of adult 
chronic recurrent parotitis without sialolithiasis, and can 
be considered a safe and efficacious treatment method. 
However, complete permanent resolution of symptoms is 
rare. We did not find any significant benefit from a single-
dose intraductal steroid injection concomitant with sialen-
doscopy but the present series is not sufficiently powered 
to determine a clinical difference between the steroid and 
non-steroid groups.
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